Sophiris Bio, Inc. (SPHS) Analysts See $-0.12 EPS

May 20, 2018 - By Richard Conner

Sophiris Bio, Inc. (NASDAQ:SPHS) LogoInvestors sentiment increased to 2.8 in Q4 2017. Its up 2.16, from 0.64 in 2017Q3. It increased, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported.
Palo Alto Investors Ltd Llc reported 247,000 shares. Geode Mgmt Lc holds 19,042 shares. Northwestern Mutual Wealth Management Co reported 400 shares. Virtu Lc holds 0.02% or 169,790 shares. Architects has 800 shares. Two Sigma Securities Ltd Co reported 0% stake. Vanguard Gru reported 784,834 shares stake. B & T Cap Dba Alpha Cap stated it has 10,128 shares. Royal Bancshares Of Canada accumulated 0% or 6,485 shares. Moreover, Wells Fargo & Company Mn has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 1,800 shares. Macquarie accumulated 0% or 3,700 shares. Natl Bank Of Montreal Can owns 11,210 shares. Jpmorgan Chase holds 0% in Sophiris Bio, Inc. (NASDAQ:SPHS) or 23,401 shares. Lpl Fincl Ltd Liability Corp has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 10,000 shares. Morgan Stanley, a New York-based fund reported 5,000 shares.

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.12 EPS on May, 21.They anticipate $0.03 EPS change or 33.33 % from last quarter’s $-0.09 EPS. After having $-0.11 EPS previously, Sophiris Bio, Inc.’s analysts see 9.09 % EPS growth. The stock increased 7.44% or $0.25 during the last trading session, reaching $3.61. About 1.04 million shares traded or 293.28% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 20, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 2 analysts covering Sophiris Bio (NASDAQ:SPHS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio has $700 highest and $600 lowest target. $6.50’s average target is 80.06% above currents $3.61 stock price. Sophiris Bio had 4 analyst reports since January 17, 2018 according to SRatingsIntel. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) has “Buy” rating given on Thursday, March 22 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, May 15 by H.C. Wainwright. Piper Jaffray initiated the stock with “Buy” rating in Friday, May 18 report. As per Wednesday, January 17, the company rating was maintained by H.C. Wainwright.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $100.87 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

More news for Sophiris Bio, Inc. (NASDAQ:SPHS) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on May 18, 2018 is yet another important article.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.